2022
Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53
2021
Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women
Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X, Busch SH, Gross CP, Richman IB. Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women. Journal Of General Internal Medicine 2021, 37: 1870-1876. PMID: 34595682, PMCID: PMC8483166, DOI: 10.1007/s11606-021-07132-6.Peer-Reviewed Original ResearchConceptsWomen 75Older womenBreast cancerAdditional cancersSubsequent imagingWomen 67Stage ITime of diagnosisEarly-stage cancerHigh rateCancer detectionConclusionsBreast cancerPrior cancerPotential confoundersScreening outcomesHealth outcomesService beneficiariesComparative effectivenessScreening mammogramsAge groupsCancerLogistic regressionResultsOur studyWomenBreast tomosynthesis